CN115335049A - 降低患者中巨噬细胞迁移抑制因子的血浆水平的方法 - Google Patents

降低患者中巨噬细胞迁移抑制因子的血浆水平的方法 Download PDF

Info

Publication number
CN115335049A
CN115335049A CN202180024762.3A CN202180024762A CN115335049A CN 115335049 A CN115335049 A CN 115335049A CN 202180024762 A CN202180024762 A CN 202180024762A CN 115335049 A CN115335049 A CN 115335049A
Authority
CN
China
Prior art keywords
cancer
day
ibudilast
disease
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180024762.3A
Other languages
English (en)
Chinese (zh)
Inventor
岩城裕一
松田和子
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medicinova Inc
Original Assignee
Medicinova Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medicinova Inc filed Critical Medicinova Inc
Publication of CN115335049A publication Critical patent/CN115335049A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN202180024762.3A 2020-04-06 2021-04-05 降低患者中巨噬细胞迁移抑制因子的血浆水平的方法 Pending CN115335049A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063005792P 2020-04-06 2020-04-06
US63/005,792 2020-04-06
PCT/US2021/025732 WO2021207054A1 (en) 2020-04-06 2021-04-05 Methods of reducing plasma level of macrophage migratory inhibitory factor in patients with ibudilast

Publications (1)

Publication Number Publication Date
CN115335049A true CN115335049A (zh) 2022-11-11

Family

ID=75674991

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180024762.3A Pending CN115335049A (zh) 2020-04-06 2021-04-05 降低患者中巨噬细胞迁移抑制因子的血浆水平的方法

Country Status (6)

Country Link
US (2) US12213966B2 (https=)
EP (1) EP4132521A1 (https=)
JP (1) JP2023521030A (https=)
CN (1) CN115335049A (https=)
CA (1) CA3174413A1 (https=)
WO (1) WO2021207054A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2745814C1 (ru) * 2020-06-05 2021-04-01 Закрытое Акционерное Общество "Биокад" Водная фармацевтическая композиция левилимаба и ее применение
CA3226898A1 (en) 2021-07-26 2023-02-02 Kazuko Matsuda Ibudilast for preventing eye cancer metastasis
US12042485B2 (en) 2021-10-07 2024-07-23 Medicinova, Inc. Methods of minimizing cancer metastasis
WO2023150093A1 (en) * 2022-02-01 2023-08-10 Medicinova, Inc. Ibudilast for use in the treatment of post-covid conditions
JP2025523822A (ja) * 2022-07-13 2025-07-25 メディシノバ・インコーポレイテッド イブジラストの注射用製剤

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090062330A1 (en) * 2007-07-11 2009-03-05 Medicinova, Inc. Treatment of progressive neurodegenerative disease with ibudilast
CN109821019A (zh) * 2017-11-06 2019-05-31 斯塔利克拉股份有限公司 用于治疗自闭症的药物组合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1106178T3 (da) 1998-08-10 2005-02-28 Kyorin Seiyaku Kk Anvendelse af ibudilast til fremstilling af et lægemiddel til behandling af dissemineret sklerose
SG148198A1 (en) 2003-11-21 2008-12-31 Combinatorx Inc Methods and reagents for the treatment of inflammatory disorders
MX2007006777A (es) 2004-12-06 2007-08-06 Avigen Inc Ibudilast para tratar dolor neuropatico y sindromes asociados.
CA2653345A1 (en) * 2006-05-31 2007-12-13 Avigen, Inc. Ibudilast for inhibiting macrophage migration inhibitory factor (mif) activity
US20110028510A1 (en) * 2009-02-18 2011-02-03 Combinatorx (Singapore) Pte. Ltd. Compositions, Methods, and Kits for Treating Influenza Viral Infections
EP3558301A4 (en) * 2016-12-22 2020-07-29 MediciNova, Inc. METHOD FOR TREATING GLIOBLASTOMA MULTIFORME WITH IBUDILAST
US20190247369A1 (en) * 2018-02-12 2019-08-15 Medicinova, Inc. Methods of suppressing myeloid-derived suppressor cells in patients

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090062330A1 (en) * 2007-07-11 2009-03-05 Medicinova, Inc. Treatment of progressive neurodegenerative disease with ibudilast
CN109821019A (zh) * 2017-11-06 2019-05-31 斯塔利克拉股份有限公司 用于治疗自闭症的药物组合物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PAUL E ROLAN等: "Ibudilast: A review of its pharmacology, efficacy and safety in respiratory and neurological disease", 《EXPERT OPINION ON PHARMACOTHERAPY》, 31 December 2009 (2009-12-31), pages 1 - 23 *

Also Published As

Publication number Publication date
US12213966B2 (en) 2025-02-04
JP2023521030A (ja) 2023-05-23
CA3174413A1 (en) 2021-10-14
EP4132521A1 (en) 2023-02-15
US20250221969A1 (en) 2025-07-10
WO2021207054A1 (en) 2021-10-14
US20210308109A1 (en) 2021-10-07

Similar Documents

Publication Publication Date Title
CN115335049A (zh) 降低患者中巨噬细胞迁移抑制因子的血浆水平的方法
TWI777515B (zh) 治療嗜伊紅性食道炎之方法
CN101848712B (zh) 用异丁地特治疗渐进性神经变性疾病
US9554987B2 (en) Methods and formulations for treating sialic acid deficiencies
US20260060964A1 (en) Methods and compositions for treating sepsis
JP2013056947A (ja) 気管支感染症の治療法
KR20260004440A (ko) 종양 괴사 인자 알파의 소분자 저해제를 사용한 건선 치료
KR20150139535A (ko) 설사 치료를 위한 방법 및 생산물
JP2017186381A (ja) シアル酸欠乏を処置するための方法および製剤
US20210177812A1 (en) Methods of suppressing myeloid-derived suppressor cells in patients
US12005049B2 (en) Methods of preventing cancer metastasis
EP2558097B1 (en) Vapendavir for the alleviation of symptoms of asthma in a subject having a HRV infection
US12042485B2 (en) Methods of minimizing cancer metastasis
CN1764457A (zh) 用于治疗阿尔茨海默病的联合疗法
CN116940350A (zh) 预防、治疗或改善溃疡性结肠炎的阿米莫德
TW202122086A (zh) 嗜中性白血球彈性蛋白酶抑制劑在肺部疾病中之使用
KR102216319B1 (ko) 히드록시유레아를 포함하는 전신성 염증 억제용 약학 조성물 및 이의 제형
WO2024129551A1 (en) Solid dosage form of a small molecule antiviral and uses thereof
HK40094222A (zh) 预防、治疗或改善溃疡性结肠炎的阿米莫德
CN121889150A (zh) 小分子抗病毒剂的固体剂型及其用途
JPS5888311A (ja) 呼吸器疾患治療剤

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination